

Kenneth A. Jones, et al
Serial No.: 09/211,755
Filed: December 15, 1998
Page 7

G⁹ Gant Accession No. 209104) --

Please add new claim 250 as follows:

G¹⁰ -250. (New) The method of claim 228, wherein the mammalian cell is non-neuronal in origin. --

A marked-up version of the Amendments showing the changes made is attached hereto as **Exhibit C**.

REMARKS

Claims 208, 210, 213, 214, 221-225, 228, 230, 231, and 233-240 were pending in the subject application. By this Amendment, applicants have added new claim 250, and amended claims 208, 213, 224, 230, and 231. Accordingly, upon entry of this Amendment, claims 208, 210, 213, 214, 221-225, 228, 230, 231, 233-240, as amended, and claim 250 will be pending and under examination.

Applicants maintain that new claim 250 and the amendments to the specification and to claims 208, 213, 224, 230, and 231 raise no issue of new matter. Support for new claim 250 may be found inter alia in the specification, as originally-filed, on page 59, lines 10-11. Applicants have amended the specification and claims 208, 213, 224, and 231 to correct SEQ ID Nos. Support for the amendments to the specification and to claims 208, 213, 224, and 231 may be found in Figures 24A-24D and Figures 25A-25D and in the Sequence Listing attached hereto as **Exhibit B**. Applicants have amended claim 230 to correct claim dependency. Accordingly, applicants respectfully request that the Amendments be entered.

Sequence Listing

The Notice indicates that there is an error involving the SEQ ID Nos assigned to the sequences set forth in Figures 24 and 25. In response, applicants submit a new Sequence Listing (**Exhibit B**), a computer diskette containing a computer readable form (CRF) of the new Sequence Listing (**Exhibit E**), and a Statement In Accordance With 37 C.F.R. §1.821(f) (**Exhibit D**).

The Sequence Listing attached hereto as **Exhibit B** has been corrected to include a sequence (SEQ ID NO: 56) which corresponds to the sequence set forth in Figures 24A-24D. Applicants maintain that the Sequence Listing attached hereto as **Exhibit B** raises no issue of new matter, as required by 37 C.F.R. §§1.821 and 1.825. Applicants have also amended the specification and claims 208, 213, 224, and 231 to provided the correct SEQ ID NOS for the sequences set forth in Figures 24A-24D and Figures 25A-25D.

New Claim 250

In the Communication, the Examiner indicated that applicants' proposed amendment of claim 229 in the Amendment In Response To July 10, 2001 Office Action, filed October 10, 2001, was not entered because claim 229 was also canceled in the same amendment.

In response, applicants have added new claim 250 which corresponds to previous claim 229.


In summary, in view of the amendments and remarks made hereinabove, applicants earnestly solicit allowance of all claims pending in the subject application, namely claims 208, 210, 213, 214, 221-225, 228, 230, 231, 233-240, and 250.

Kenneth A. Jones, et al
Serial No.: 09/211,755
Filed: December 15, 1998
Page 9


If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this Amendment. However, if a fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Alan D. Miller
Registration No. 42,889
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents Washington, D.C. 20231.	
	1/30/02
John P. White Reg. No. 28,678	Date